The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Whole-genome sequencing–based ultra-sensitive ctDNA molecular residual disease assessment in resectable gastric cancer: Results from MONSTAR-SCREEN-3.
 
Etsuro Bando
Speakers' Bureau - DAIICHI SANKYO COMPANY, LIMITED; Intuitive Surgical; Johnson & Johnson; KAKEN PHARMACEUTICAL CO., LTD; Ono Pharmaceutical; Tsumura & Co.
 
Masahiro Yura
No Relationships to Disclose
 
Yusuke Koseki
No Relationships to Disclose
 
Itaru Yasufuku
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Covidien; Johnson & Johnson/MedTech; MSD Oncology; Ono Pharm.
 
Akitaka Makiyama
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Kazunari Misawa
No Relationships to Disclose
 
Yasuo Tsuda
No Relationships to Disclose
 
Satoru Matsuda
Honoraria - Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo/Lilly; Ethicon; MSD; Olympus Medical Systems; Ono Pharmaceutical; Syxmex; Syxmex
 
Masaya Nakauchi
No Relationships to Disclose
 
Souya Nunobe
No Relationships to Disclose
 
Takashi Oshima
No Relationships to Disclose
 
Shinji Hato
No Relationships to Disclose
 
Toshiaki Shichinohe
No Relationships to Disclose
 
Kazuyoshi Yamamoto
No Relationships to Disclose
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Guardant Health; Miyarisan pharmaceutical; Myriad Genetics; Takata Pharmaceutical
Consulting or Advisory Role - Guardant Health
 
Izuma Nakayama
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/UCB Japan
Research Funding - Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Jeff Jasper
Employment - Myriad Genetics
Stock and Other Ownership Interests - Myriad Genetics
Travel, Accommodations, Expenses - Myriad Genetics
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Takahiro Kinoshita
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Gunze; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Medtronic; MSD; Olympus Medical Systems; Ono Pharmaceutical; Smart hospital
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Daiichi Sankyo; Johnson & Johnson K.K; Medtronic; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Tsumura & Co.